Ladonna

Dienogest/Ethinylestradiol, the active ingredient in Ladonna, is a combined oral contraceptive presented as an oral tablet for oral use. It is indicated for contraception and regulation of menstrual cycles in women of reproductive age.

GNH USA supplies Ladonna as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ladonna, a combined oral contraceptive, is used to manage hormonal contraception and menstrual cycle regulation.

- Contraception: provides effective prevention of pregnancy. - Menstrual cycle regulation: helps to regularize cycle length and reduce irregular bleeding. - Dysmenorrhea management: may lessen menstrual pain and associated symptoms.

Ladonna may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like. - Breast tenderness: swelling or discomfort. - Spotting or breakthrough bleeding: irregular light bleeding. - Weight gain: modest increase in body weight. - Mood changes: irritability or emotional fluctuations.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins. - Pulmonary embolism: clot migration to lungs. - Stroke: cerebrovascular accident. - Myocardial infarction: heart attack. - Severe allergic reaction: anaphylaxis, hives, swelling. - Liver tumor: benign hepatic adenoma.

Before prescribing Ladonna, clinicians should evaluate individual risk factors and counsel patients on safe use.

- Cardiovascular risk assessment: review history of hypertension, clotting disorders, or smoking. - Liver function review: avoid use in severe hepatic impairment. - Smoking status: advise against use in women over 35 who smoke. - Missed dose guidance: provide clear instructions for handling forgotten tablets. - Concomitant medication review: assess for drugs that may affect efficacy. - Store at ambient temperature: keep in the original pack, protect from moisture.

Ladonna can interact with several medicines, altering its effectiveness or increasing adverse risk.

Major Interactions (Avoid): - Enzyme‑inducing antiepileptics (e.g., carbamazepine, phenytoin): reduce hormonal levels. - Rifampin or other strong inducers: decrease contraceptive efficacy. - Protease inhibitors (e.g., ritonavir): may increase estrogen exposure. - Certain antibiotics (e.g., griseofulvin): lower hormone concentrations. - Anticoagulants (e.g., warfarin): may alter clotting parameters.

Moderate Interactions (Monitor Closely): - SSRIs (e.g., fluoxetine): may increase bleeding tendency. - Macrolide antibiotics (e.g., erythromycin): can raise estrogen levels. - St. John’s Wort: may diminish contraceptive effect. - Antifungals (e.g., ketoconazole): elevate hormone concentrations. - NSAIDs (e.g., ibuprofen): may raise blood pressure risk.